Intranasal medication delivery device and method of use thereof

• US 9,949,989 B2
• Filed: 04/15/2015
• Issued: 04/24/2018
• Est. Priority Date: 04/16/2014
• Status: Active Grant

• Current Assignee: William R. Ackerman
• Original Assignee: John T. Given, William R. Ackerman
• Inventors: Given, John T., Ackerman, William R.
• Primary Examiner(s): BARKER, MICHAEL P
• Application Number:
  US14/687,408
• Publication Number:
  US 20150297617A1
• Time in Patent Office: 1,105 Days
• Field of Search: None
• CPC Class Codes: A61B 17/24 for use in the oral cavity, larynx, bronchial passages or nose for medical inspection of cavities or tubes in the body A61B1/00; Tongue scrapers
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/4468 having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/616 by carboxylic acids, e.g. acetylsalicylic acid
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61M 15/08 Inhaling devices inserted into the nose
• CPC Class Codes: A61M 16/104 specially adapted for anaesthetics A61M16/18 takes precedence
• CPC Class Codes: A61M 2210/0618 Nose
• CPC Class Codes: A61M 31/00 Devices for introducing or retaining media, e.g. remedies, in cavities of the body A61M25/00 takes precedence ; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008

Abstract

The intranasal medication delivery device and method of use thereof includes an elongated malleable member arcuately curved or pre-formed in manner complimentary to the anterior wall of a nasal cavity. One particular embodiment provides the elongated and arcuate member to deliver medication through a lumen such that the medication is deposited in a semi-solid state adjacent the anterior aspect of the nasal cavity lateral wall and to the anterior end of the superior, middle, and inferior turbinate. Another particular embodiment provides the elongated and arcuate member to deliver medication as a suppository to a location similar to that of the previous embodiment. The method of delivering the medicine provides depositing the medicine adjacent the anterior end of one of the superior turbinate, middle turbinate, and inferior turbinate. An exemplary medication can be any one of a corticosteroid, an anti-histamine, an immune active mediator, an IgE binding medication, or a decongestant.

Claims

1. An intranasal treatment method for nasal tissues within a nasal cavity of a patient, the nasal tissues including a superior turbinate, a middle turbinate, and an inferior turbinate, each turbinate extending anteroposteriorly, comprising the steps of:

providing a medicine, the medicine including an amount of a corticosteroid;

depositing the medicine adjacent one of the superior turbinate, middle turbinate, and inferior turbinate;

depositing a first portion of medicine adjacent the superior turbinate;

depositing a second portion of medicine adjacent the middle turbinate; and

depositing a third portion medicine adjacent the inferior turbinate; and

depositing the medicine in a first phase state having a first viscosity, wherein the medicine heats up within the nasal cavity and transitions into a second phase state having a second viscosity, wherein second viscosity is lower than the first viscosity.

2. The method of claim 1, wherein the first portion of medicine is deposited in a targeted manner adjacent an anterior end of the superior turbinate;

wherein the second portion of medicine is deposited in a targeted manner adjacent an anterior end of the middle turbinate; and

wherein the third portion of medicine is deposited in a targeted manner adjacent an anterior end of the inferior turbinate.

3. The method of claim 1, further comprising the step of:

effecting the transition of the medicine from the first phase state to the second phase state, such that the medicine flows to coat one of the superior, middle, and inferior turbinate.

4. The method of claim 3, wherein the transition of the medicine from the first phase state to the second phase state is accomplished by melting, wherein the medicine has a melting point of about 90°

F. to about 100°

F.

5. The method of claim 3, wherein the medicine is displaced via gravity from a first position adjacent an anterior aspect of a lateral wall defining a portion of the nasal cavity to a second position adjacent a nasal ostea posterior to the first position.

6. The method of claim 3, wherein the medicine is a non-Newtonian fluid at the first phase state and wherein the medicine is a Newtonian fluid at the second phase state.

7. The method of claim 3, prior to the step of depositing the medicine, further comprising the steps of:

inserting the medicine carried by a delivery device into the nasal cavity, a portion of the delivery device having an arcuate configuration complementary to a nasal cavity anterior wall; and

ejecting the medicine from the delivery device.

8. The method of claim 7, wherein the delivery device includes a proximal end and a distal end, and defines a lumen, and wherein prior to the step of depositing the medicine further comprises the steps of:

inserting the distal end of the delivery device through a nostril until the distal end of the delivery device is adjacent an anterior end of the superior turbinate; and

drawing the delivery device outward from the nasal cavity through the nostril while simultaneously ejecting the medicine through the lumen.

9. The method of claim 3, prior to the step of depositing the medicine, further comprising the steps of:

inserting the medicine through a nostril, the medicine integrally formed in a self-supporting generally rigid member.

10. The method of claim 9, wherein the self-supporting generally rigid member has an arcuate configuration curved complementary to a curvature of a nasal cavity anterior wall.

11. The method of claim 3, prior to the step of depositing the medicine, further comprising the step of:

inserting the medicine through a nostril, the medicine integrally formed in a flexible linear suppository; and

bending the flexible linear suppository, wherein the suppository is linear in an undelivered position outside the nasal cavity, and the suppository is arcuate in a delivered position inside the nasal cavity.

12. The method of claim 11, wherein the step of inserting a flexible linear suppository into the nasal cavity is accomplished by rotating the suppository, wherein the suppository includes a plurality of helically extending edges winding about a longitudinal axis of the suppository.

13. An intranasal treatment method for nasal tissues within a nasal cavity of a patient, the nasal tissues including a superior turbinate, a middle turbinate, and an inferior turbinate, each turbinate extending anteroposteriorly, comprising the steps of:

providing a medicine, the medicine including an amount of a corticosteroid;

depositing the medicine adjacent one of the superior turbinate, middle turbinate, and inferior turbinate, wherein the superior and middle turbinate define a first passageway therebetween, the middle and inferior turbinate define a second passageway therebetween, and the inferior turbinate and a floor of the nasal cavity define a third passageway therebetween;

depositing the medicine adjacent one of the first, second, and third passageways;

depositing a first portion of the medicine adjacent the first passageway;

depositing a second portion of the medicine adjacent the second passageway;

depositing a third portion of the medicine adjacent the third passageway;

wherein the first portion of medicine is deposited in a targeted manner adjacent an anterior end of the first passageway;

wherein the second portion of medicine is deposited in a targeted manner adjacent an anterior end of the second passageway;

wherein the third portion of medicine is deposited in a targeted manner adjacent an anterior end of the third passageway;

depositing a bead of medicine in a first phase state at a first viscosity wherein the bead of medicine heats up within nasal cavity and transitions into a second phase state at a second viscosity such that the medicine moves along one of the first, second, and third passageways; and

wherein the second viscosity is lower than the first viscosity.

14. An intranasal treatment method for nasal tissues within a nasal cavity of a patient, the nasal tissues including a superior turbinate, a middle turbinate, and an inferior turbinate, each turbinate extending anteroposteriorly, comprising the steps of:

providing a medicine, the medicine including an amount of a corticosteroid;

depositing the medicine adjacent one of the superior turbinate, middle turbinate, and inferior turbinate, wherein the medicine is in one of (i) a semi-solid state and (ii) a solid state, further comprising the step of;

moving the patient to a supine position, wherein the medicine heats up within nasal cavity and melts from either (i) the semi-solid state and (ii) the solid state into a liquid and the medicine flows posteriorly under gravitation force.